29 April 2008
The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients
Silvia TirelliA, Mariano FerraressoACDE, Luciana GhioBD, Elisa MeregalliF, Valentina MartinaB, Mirco BelingheriF, Camilla MattielloF, Emilio TorresaniG, Alberto EdefontiGMed Sci Monit 2008; 14(5): CR251-254 :: ID: 855750
Abstract
Background
CYP3A5 gene polymorphism has been shown to influence tacrolimus (TAC) blood concentration and dose requirement in adult kidney transplant patients. The aim was to analyze retrospectively the modification induced by CYP3A5 gene polymorphism on TAC's pharmacokinetic parameters obtained from 26 adolescents receiving TAC as their main immunosuppressive drug.
Material and Method
The adolescent kidney transplant patients were genotyped for CYP3A5*3 and grouped accordingly. TAC dose, blood levels, and dose-normalized TAC blood concentration and volume of distribution obtained at different post-transplant periods during the first post-transplant year were correlated with the corresponding genotype.
Results
During the first three months post-transplant, heterozygotes (CYP3A5*1/*3) displayed a lower TAC blood concentration than homozygotes (CYP3A5*3/*3) (at 1 month: 7.8+/-2.1 vs. 13.4+/-6 ng/ml, p=0.007) despite a therapeutic monitoring strategy. Between 3-12 months post-transplant, TAC blood concentration was comparable between the two groups, but a two-fold increase in the daily drug dose was necessary for the heterozygotes (at 6 months: 0.23+/-0.1 vs. 0.13+/-0.06 mg/kg, p=0.04). The dose-normalized TAC concentration [(ng/ml)/(mg/kg)] was significantly lower in patients displaying the CYP3A5*1/*3 polymorphism (at 2 weeks: 33+/-2.16 vs. 71.1+/-37.8, p=0.01; 6 months: 35.4+/-12.9 vs. 85.2+/-58.9, p=0.01). At the same time, the volume of distribution of the drug in the latter group was distinctly increased for the entire post-transplant year (at 6 months: 1.79+/-0.42 vs. 0.73+/-0.5 l/kg, p=0.001).
Conclusions
The great influence of CYP3A5 on the pharmacokinetics and pharmacodynamics of TAC in young transplant recipients suggests the need for pre-transplant screening of this polymorphism to improve TAC therapy.
Keywords: Tacrolimus - pharmacokinetics, Polymorphism, Genetic, Kidney Transplantation - methods, Kidney - drug effects, Immunosuppressive Agents - pharmacokinetics, Homozygote, Heterozygote, Genotype, Cytochrome P-450 CYP3A - genetics, Polymorphism, Single Nucleotide, Child, Alleles, Adolescent
Editorial
01 January 2025 : Editorial
Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?DOI: 10.12659/MSM.947707
Med Sci Monit 2025; 31:e947707
In Press
Clinical Research
Impact of Smovey Vibration Versus Dumbbell Resistance on Muscle Activation in WomenMed Sci Monit In Press; DOI: 10.12659/MSM.946567
Clinical Research
Five-Year Impact of Weight Loss on Knee Pain and Quality of Life in Obese PatientsMed Sci Monit In Press; DOI: 10.12659/MSM.946550
Clinical Research
Butorphanol Tartrate Nasal Spray for Post-Cesarean Analgesia and Prolactin SecretionMed Sci Monit In Press; DOI: 10.12659/MSM.945224
Database Analysis
Role of the Carhart Effect and Outcomes from Surgery: A Retrospective Study of 532 Patients with Conductive...Med Sci Monit In Press; DOI: 10.12659/MSM.947061
Most Viewed Current Articles
17 Jan 2024 : Review article 6,963,045
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 700,086
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 23,449
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 18,141
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912